A Pan-European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in type 1 and type 2 diabetes

Journal of Diabetes Science and Technology

Volumn 5, Issue 5, 2011, Pages 1224-1234

  Hancu, Nicolae ^a   Czupryniak, Leszek ^b   Genestin, Elisabeth ^c   Sourij, Harald ^d  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c SANOFI   (France)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

European; Insulin glargine; Insulin glulisine; Insulin pen device; Patient satisfaction; SoloSTAR

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ADULT; AGED; ARTICLE; CANADA; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; EUROPE; FEMALE; HEALTH SURVEY; HUMAN; INSTRUMENTATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; CANADA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; EUROPE; FEMALE; HEALTH SURVEYS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES;

EID: 84857417968     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681100500531     Document Type: Article

References (23)

1. Davis EM, Bebee A, Crawford L, Destache C. Nurse satisfaction using insulin pens in hospitalized patients. Diabetes Educ. 2009;35(5):799-809.
2. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26 Suppl 3:S18-24.
3. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1710-25.
4. Robertson KE, Glazer NB, Campbell RK. The latest developments in insulin injection devices. Diabetes Educ. 2000;26(1):135-8, 141-6, 149-52.
5. IMS Health. IMS MidasTM June 2009 insulin sales volume.
6. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29 Spec No:1294-305.
7. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12 Suppl 1:S101-8.
8. Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv. 2007;4(2):165-74.
9. Friedrichs A. Dose accuracy of SoloSTAR and FlexPen as assessed in a clinical setting. Diabetes Technol Ther. 2009;11(9):609-13.
10. Hermanns N, Kulzer B, Haak T. Dosing accuracy with a novel pen device (SoloSTAR) as performed by patients with diabetes in a clinical setting. Diabetes Technol Ther. 2008;10(4):322-7.
11. Penfornis A, Horvat K. Dose accuracy comparison between SoloSTAR and FlexPen at three diferent dose levels. Diabetes Technol Ther. 2008;10(5):359-62.
12. Pfützner A, Asakura T, Sommavilla B, Lee W. Insulin delivery with FlexPen: dose accuracy, patient preference and adherence. Expert Opin Drug Deliv. 2008;5(8):915-25.
13. Papanas N, Maltezos E. The diabetic hand: a forgotten complication? J Diabetes Complications. 2010;24(3):154-62.
14. Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol. 2008;126(12):1740-7.
15. Centers for Disease Control and Prevention. Prevalence of visual impairment and selected eye diseases among persons aged ≥50 years with and without diabetes - United States, 2002. http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5345a3.htm. Accessed January 29, 2011.
16. Williams A. Diabetes and visual impairment - identifying needs, ensuring full accessibility. Diabetes Voice. 2008;53(3).
17. Haak T, Edelman S, Walter C, Lecointre B, Spollett G. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study. Clin Ther. 2007;29(4):650-60.
18. Carter J, Roberts A. Usability of a pre-filled insulin injection device in a 3-month observational survey of everyday clinical practice in Australia. Curr Med Res Opin. 2008;24(10):2741-9.
19. Carter J, Beilin J, Morton A, De Luise M. Usability, participant acceptance, and safety of a prefilled insulin injection device in a 3-month observational survey in everyday clinical practice in Australia. J Diabetes Sci Technol. 2009;3(6):1425-38.
20. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-9.
21. Krzywon M, Abdel-Tawab M, van der Burg T, Fuhr U, Schubert-Zsilavecz M. Dosing accuracy of commonly used disposable insulin pens. Curr Med Res Opin. 2010;26(4):901-5.
22. Weise A, Pfützner JW, Borig J, Pfützner AM, Safinowski M, Hänel H, Musholt PB, Pfützner A. Comparison of the dose accuracy of prefilled insulin pens. J Diabetes Sci Technol. 2009;3(1):149-53.
23. Williams AS, Schnarrenberger PA. A comparison of dosing accuracy: visually impaired and sighted people using insulin pens. J Diabetes Sci Technol. 2010;4(3):514-21.